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Identity 
FAB criteria AML M3: 
Great majority of cells are abnormal promyelocytes, 
with a characteristic pattern of heavy granulation. 
Characteristic cells contain bundles of Auer rods 
('faggots'). 
FAB criteria AML M3v: 
Minimal granulation, relative scarcity of cells with 
heavy granulation and cells containing multiple Auer 
rods. The nucleus of every cell in the peripheral blood 
is bilobed, multilobed or reniform, but the majority of 
cells are either devoid of granules or contain only a few 
fine azurophil granules. However, at least a few cells 
with all the cytoplasmic features of typical AML M3 
are present. If these are overlooked, the cases are likely 
misdiagnosed as atypical monocytic leukemia. The 
atypical morphology is mainly a feature of the 
peripheral blood cells - bone marrow morphology is 
closer to that of typical AML M3. 
Both subtypes show a very strong myeloperoxidase 
reaction and a negative reaction for non-specific 
esterase. 
Immunophenotype: 
Characteristic but not diagnostic myeloid phenotype. 
CD33 positive, HLA-DR is generally absent. 
In M3 but not M3v: characteristic light scatter pattern, 
strong unspecific fluorescence signal. 
WHO classification: 
Distinct entity in category AML with recurrent genetic 
abnormalities: Acute promyelocytic leukemia (AML 
with t(15;17)(q22;q12) (PML / RARA) and variants). 
 
Clinics and pathology 
Epidemiology 
Rare: 5-8 % of ANLL, incidence higher in Spain, Italy 
and Latinos; occurs at any age, predominantly adults in 
mid-life accounting for aprox. 5% of treatment relat d 
leukemias (t-AML). 
Clinics 
Low WBC in AML M3, high WBC in AML M3v; 
frequently associated with disseminated intravascular 
coagulation (DIC) and hyperfibrinolysis. 
Cytology 
The cytomorphology of APL blasts is obviously 
different in the two subtypes: in AML M3, the 
abnormal promyelocytes show a heavy granulation and 
bundles of Auer rods; in AML M3v blasts have a non- 
or hypogranular cytoplasm or contain fine dustlike 
cytoplasmic granules that may not be apparent by light
microscopy. Furthermore, M3v blasts show a typical 
bilobed nuclear configuration. This latter morphologic 
phenotype, together with missing granulation, often 
resulted in the misleading diagnosis of acute monocytic 
or myelo-monocytic leukemia before the cytogenetic 
correlation of both AML M3 and M3v with 
t(15;17)(q22;q12) was observed. AML M3v accounts 
for approximately 1/3 of APL cases. 
Prognosis 
Favourable if treated with an ATRA (all trans-retinoic 
acid) and anthracycline containing regimen: CR in 
>80% of cases, med survival: in most studies with  
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ATRA treatment not reached yet, adverse prognosis 
factors: high WBC, FLT3 - internal tandem duplication 
(ITD), bleeding episodes. 
Cytogenetics 
Cytogenetics morphological 
t(15;17)(q22;q12) leading to a PML-RARA-
rearrangement on the molecular level. 
Variant translocations involving one ore more 
chromosomes in addition to 15 and 17 are found in 2-
5% of cases with PML-RARA-rearrangement. 
Cytogenetically cryptic PML-RARA-rearrangements 
are observed in 2-3% of APL cases. 
Additional anomalies 
Are observed in 35-45% of cases, most frequent: +8, 
del(9q), ider(17)(q10)t(15;17). 
Variants 
3 variant translocations involving RARA: 
t(11;17)(q23;q12) leading to a fusion of RARA and 
PLZF; t(5;17)(q23;q12) leading to a fusion of RARA 
and NPM; t(11;17)(q13;q12) leading to a fusion of 
RARA and NuMA. The cases with variant 
translocation have initially been reported as having 
APL morphology. However, morphological differences 
exist. Clinically important is that APL variant with 
t(5;17)(q12;q12) seems to respond to ATRA, while 
APL variant with t(11;17)(q23;q12) does not. 
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